
FDA inspections can create uncertainty. Supervision of the contract manufacturer is crucial in ensuring compliance.
Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

FDA inspections can create uncertainty. Supervision of the contract manufacturer is crucial in ensuring compliance.

Outsourcing of manufacturing activities is expected to increase in 2019.

The growth in adoption of single-use systems for commercial manufacturing will be dramatic in coming years.

This article highlights 15 years of changes in biopharmaceutical manufacturing.

Development and adoption of new technologies create challenges that may take years to resolve.

The biopharma industry is growing at 14-15%, but efficiency demands and lack of skilled labor may impact performance.

Innovation speeds discovery, drives down costs, and improves productivity.

Published: September 2nd 2017 | Updated:

Published: October 4th 2017 | Updated:

Published: March 2nd 2018 | Updated:

Published: July 2nd 2018 | Updated:

Published: November 2nd 2018 | Updated:

Published: January 2nd 2019 | Updated: